Decoding Lung Cancer Targets Using Solanum Trilobatum: An In Silico Approach

Abstract

Background: Lung cancer is a major global health burden, characterized by high mortality rates and limited effectiveness of existing therapeutic strategies. The search for novel, targeted and less toxic anticancer agents has led to increased in medicinal plants. Solanum trilobatum, a well- known medicinal plant in traditional medicine possesses a wide range of bioactive phytochemicals with reported pharmacological properties including anticancer activity. This study explores the potential of Solanum trilobatum phytocompounds against lung cancer- associated molecular targets using In silico approaches.

Objective: To identify and characterize the key phytoconstituents present in Solanum trilobatum extract with potential anticancer activity. To perform In silico molecular docking studies of selected phytoconstituents against lung cancer-related target proteins ( EGFR, VEGF, ALK, ROS1, c-MET) to predict binding affinity and interaction mechanism.

Key findings: Key molecular targets involved in lung cancer progression such as epidermal growth factor receptor (EGFR), Vascular endothelial growth factor (VEGF), Anplastic lymphoma kinase (ALK), ROS proto oncogene (ROS1), Mesechymla epithelilal transition factor (c-MET) signalling proteins were reviwed for computational analysis. Results of Molecular docking studies were revealed strong binding affinities and stable interactions, suggesting the potential inhibitory effects of the phytocompounds of Solanum trilobatum on critical cancer related pathways.

Conclusion: The study revealed that phytoconstituents of Solanum trilobatum could be considered as the promising inhibitor against lung cancer.